Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EDP-305 and Oral Contraceptive Interaction Study
NCT03783897Phase 1Completed
- Sponsor
- Enanta Pharmaceuticals
- Start
- Nov 2018
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of EDP-305 in Nonalcoholic steatohepatitis (NASH), sponsored by Enanta Pharmaceuticals. Primary endpoints: Area under the plasma concentration-time curve for Oral Contraceptive and Maximum plasma concentration for Oral Contraceptive. Started Nov 2018; status: completed.
02
Drugs
EDP-305
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT03783897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03783897.